Celldex Therapeutics, founded in Hampton, United States, is a clinical-stage biotechnology company focused on developing monoclonal and bispecific antibodies to treat diseases with inadequate existing treatments. The company's core mission is to leverage the human immune system and target critical pathways to improve patient outcomes in inflammatory diseases and various cancers. Celldex's innovative pipeline aims to create transformative antibody-based therapeutics that address significant unmet medical needs.

Notable individuals affiliated with Celldex include its leadership team and scientific advisors who are experts in immunology and oncology. The company has garnered attention from investors and the scientific community, presenting at major conferences like the Jefferies Healthcare Conference. Key achievements include initiating phase studies and demonstrating significant improvements in clinical trials. Celldex's impact lies in its potential to revolutionize treatment paradigms for severe diseases, offering hope to patients with limited options.